[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transcranial-magnetic-stimulation-repetitive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transcranial-magnetic-stimulation-repetitive":159},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,60,92,117,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100574927","the-effect-of-non-invasive-brain-stimulation-rtms-on-hand-muscles-in-chronic-stroke-patients-100574927",false,"NCT06765642","The Effect of Non-invasive Brain Stimulation rTMS on Hand Muscles in Chronic Stroke Patients.","Evaluation of 3 Patterned rTMS Stimulation Dosage on Corticospinal Excitability and Motor Learning in Stroke Patients","REALISE","Inclusion criteria:\n\n1. Age \\>=21 years old of any race or gender\n2. First-ever ischemic or hemorrhagic stroke (neuroimaging verified) at least 3 months from stroke onset\n3. Unilateral arm weakness measured by FM-UM scale \\\u003C= 62 out of 66\n4. Inducible rest motor threshold and testing motor threshold recorded from the affected first dorsal interosseous (FDI) muscle from the study subject\n\nExclusion criteria\n\n1. Bilateral strokes (infarcts and\u002For hematoma)\n2. Other co-existent neuromuscular disorders affecting upper extremity motor impairment.\n3. History of medically uncontrolled depression or other neuropsychiatric disorders despite medications either before or after a stroke that may affect the subject's ability to participate in the study.\n4. Uncontrolled hypertension despite medical treatment(s) at the time of randomization, defined as SBP≥185 mmHg or DBP≥110 mmHg (patient can be treated, reassessed and randomized later).\n5. Presence of any MRI\u002FrTMS risk factors including but not limited to:\n\n   1. an electrically, magnetically, or mechanically activated metallic or nonmetallic implant including cardiac pacemaker, intracerebral vascular clips or any other electrically sensitive support system.\n   2. a non-fixed metallic part in any part of the body, including a previous metallic injury to the eye.\n   3. history of seizure disorder before stroke or seizure after stroke.\n   4. preexisting scalp lesion or bone defect or hemicraniectomy.\n6. Concurrent enrollment in another interventional stroke recovery study.\n7. Concerns that the subject cannot comply with study procedures and visits.\n8. Pregnant individuals","ALL","21 Years",{"count":20,"type":21},26,"ESTIMATED","INTERVENTIONAL",[24],"NA","The study is about using a brain stimulation technique called rTMS (Repetitive Transcranial Magnetic Stimulation) to help improve hand muscles in people who had a stroke. Researchers want to understand how this device can help stroke patients use their hands better.",[27,28,29,30,31,32,33,34,35],"Stroke","Stroke Patients","Arm Weakness as a Consequence of Stroke","Brain Stimulation","Transcranial Magnetic Stimulation Repetitive","Transcranial Magnetic Stimulation","Motor Learning","Chronic Stroke Patients","Chronic Stroke Survivors",[37,38,39,40,41,42,43,44,45,46],"stroke","arm weakness","arm weakness as a consequence of stroke","stroke patients","transcranial magnetic stimulation","transcranial magnetic stimulation repetitive","motor learning","chronic stroke","chronic stroke patients","chronic stroke survivors","RECRUITING","2026-05-19",{"date":50,"type":51},"2026-05-22","ACTUAL",{"date":53,"type":51},"2025-06-09",{"date":55,"type":21},"2027-04-30",{"name":57,"class":58},"Duke University","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":59},"100609160","scalp-acupuncture-combined-with-rtms-for-upper-limb-motor-dysfunction-in-stroke-a-brain-network-study-100609160","NCT07210944","Scalp Acupuncture Combined With rTMS for Upper Limb Motor Dysfunction in Stroke: A Brain Network Study","Research Protocol for a Randomized Controlled Trial on Brain Network Study of Upper Limb Motor Dysfunction in Stroke Patients Treated With Scalp Acupuncture Combined With rTMS","Inclusion Criteria:\n\n* Meet the diagnostic criteria for stroke (symptoms and signs, imaging indicators, etc.), and are independently diagnosed by two deputy chief physicians\n* Age 18-70 years old, first episode, duration 1-6 months\n* The diagnostic criteria for upper limb dysfunction align with the Brunnstrom staging system: patients in Brunnstrom stages II to IV. Stage II: patients exhibit associative responses and can perform coordinated movements, with minimal voluntary movements; Stage III: patients show voluntary coordinated movements, such as grasping with the hand but not extending; Stage IV: patients can perform isolated movements, such as pinching with the hand and limited extension\n* No severe visual or hearing impairment, able to cooperate with relevant assessments and tests\n* The score of the Mini-Mental State Examination is ≥20 points\n* Vital signs are stable, with no signs of progressive neurological symptoms\n* The patient or legal guardian agrees and signs the informed consent form\n\nExclusion Criteria:\n\n* Severe visual impairment, hemispatial neglect, body image disorder\n* Individuals who cannot undergo rTMS treatment due to reasons such as metal implants, cardiac pacemakers, or skull defects\n* Previous history of brain tumor, brain trauma, epilepsy, and risk of epileptic seizures\n* Any other factors that affect assessment and treatment\n* Dysfunction of limb movement caused by other reasons (such as trauma, etc.)","18 Years","70 Years",{"count":70,"type":21},44,[24],"This study aims to compare the improvement effects of the rTMS (repetitive transcranial magnetic stimulation) combined with conventional rehabilitation therapy group with the rTMS combined with scalp acupuncture and conventional rehabilitation therapy group. Through statistical analysis of the results obtained from functional near-infrared spectroscopy technology during task states, the investigators elucidate the neuroregulatory mechanism of scalp acupuncture combined with rTMS in improving upper limb motor function in stroke patients under MEP localization, and provide evidence for a more optimal rehabilitation program for post-stroke upper limb motor dysfunction.",[74,75,27,31,76],"Upper Extremity","Acupuncture Therapy","Motor Disorders",[78,79,80,81,76],"Conventional rehabilitation therapy","Scalp Acupuncture","Upper Limb","Repetitive Transcranial Magnetic Stimulation","NOT_YET_RECRUITING","2025-11-18",{"date":85,"type":51},"2025-11-19",{"date":87,"type":21},"2025-12-05",{"date":89,"type":21},"2027-05-30",{"name":91,"class":58},"Debiao Kong",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":113,"leadSponsor":115,"locationsCount":59},"100599575","individualized-location-based-rtms-for-migraine-treatment-a-multicenter-clinical-study-100599575","NCT07086274","Individualized Location-based rTMS for Migraine Treatment: A Multicenter Clinical Study","Efficacy of Individualized Location-based Repetitive Transcranial Magnetic Stimulation in the Treatment of Migraine: a Prospective Clinical Study","individua rTMS","Inclusion Criteria:\n\n* Aged between 18 and 65 years; both men and women.\n* Diagnosis of migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-III), with first onset before age 50 and a history of migraine for more than 1 year.\n* Migraine frequency of ≥4 days per month during both the 3 months prior to the screening period and the screening period itself.\n* Informed consent documents are signed, and subjects are cooperative with the evaluation and rTMS treatment, having been informed of known and potential risks and available alternative treatments.\n\nExclusion Criteria:\n\n* Patients with contraindications to TMS (e.g., metal implants, pacemakers).\n* Severe anxiety or depression (HAMD score \\>35, HAMA score \\>29).\n* History of migraine prophylactic drug adjustment during the screening and treatment period.\n* Aphasia or cognitive dysfunction (MMSE score ≤23).\n* Pregnancy or lactation.\n* Clinicians assess severe comorbidities that are not treatable.","65 Years",{"count":102,"type":21},152,[24],"For migraine patients experiencing at least four attack days per month and undergoing transcranial magnetic stimulation (TMS) treatment, a randomized, double-blind controlled trial is conducted, dividing participants into a traditional targeting group and an individualized targeting group. Patients in both groups are followed up before treatment and at 1, 2, and 3 months post-treatment, evaluating the following parameters: migraine diaries, the number of migraine days, rescue medication usage, headache intensity, the number of moderate-to-severe migraine days, and the proportion of patients achieving a ≥50% reduction in migraine days. Further assessments include changes in the Migraine Disability Assessment (MIDAS), Headache Impact Test-6 (HIT-6), Migraine-Specific Quality of Life Questionnaire (MSQ), Pittsburgh Sleep Quality Index (PSQI), Patient Global Impression of Change (PGIC), 24-item Hamilton Depression Scale (HAMD-24), and 14-item Hamilton Anxiety Scale (HAMA-14). Biomarker and metabolic analyses include tryptophan and kynurenine metabolism, calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-activating polypeptide (PACAP), vasoactive intestinal peptide (VIP), neuropeptide Y (NPY), substance P, endothelin-1, inflammatory cytokines (IL-1β, IL-6, TNF-α, TGF-β1), glutamate, endocannabinoids and related lipids, as well as gut microbiota composition. Additionally, changes in resting-state functional magnetic resonance imaging (rs-fMRI) before and after treatment are analyzed. This study aims to compare the efficacy of TMS treatment under different targeting strategies in migraine patients, providing theoretical support for clinical applications.",[106,31],"Migraine",[108],"Individualized location-based","2025-07-18",{"date":111,"type":51},"2025-07-25",{"date":111,"type":21},{"date":114,"type":21},"2027-07-25",{"name":116,"class":58},"First Affiliated Hospital of Zhejiang University",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":100,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":141,"leadSponsor":143,"locationsCount":59},"100573487","intermittent-theta-burst-stimulation-in-fibromyalgia-syndrome-100573487","NCT06746922","Intermittent Theta Burst Stimulation in Fibromyalgia Syndrome","The Effect of Intermittent Theta Burst Stimulation to the Primary Motor Cortex on Pain Intensity, Pain Catastrophizing, Quality of Life and Mood in Fibromyalgia Patients","Inclusion Criteria:\n\n* Being between the ages of 18-65\n* Being diagnosed with fibromyalgia syndrome (according to 2016 criteria)\n* Average pain intensity of NRS ≥ 4\u002F10\n* Fibromyalgia treatment was stable for the last 3 months and no treatment change was planned during the study\n\nExclusion Criteria:\n\n* Having a clinical condition that would constitute a contraindication for TMS (metallic implant, cardiac pacing, pregnancy, epilepsy, head trauma, history of cranial operation...)\n* Presence of malignancy\n* Systemic rheumatologic diseases\n* Major orthopedic problems limiting activities of daily living (gait disturbance or fracture sequelae limiting joint mobility, prostheses, nerve-tendon injuries)\n* Serious neurological diseases (increased intracranial pressure, presence of space-occupying lesions in the brain, history of epilepsy, presence of cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, history of previous head trauma causing loss of consciousness)\n* Alcohol or drug addiction\n* History of major depression\u002Fpersonality disorder or psychosis\n* Having received TMS treatment before\n* Taking benzodiazepine, gabapentin\u002Fpregabalin or anticonvulsant medications that have the potential to interfere with intermittent theta burst stimulation treatment or have taken them within the last 4 weeks\n* Pregnant or planning pregnancy or breastfeeding",{"count":125,"type":21},30,[24],"Research on repetitive transcranial magnetic stimulation therapy in fibromyalgia syndrome (FMS) is increasing rapidly. High-frequency rTMS administration to FMS patients is reported to restore intracortical facilitation and provide successful pain relief. This finding supports restoration of cortical stimulation as one of the possible mechanisms of action for rTMS. One treatment protocol is intermittent theta burst stimulation (iTBS, a variant of excitatory rTMS). Although there are many treatment protocols, there are few widely accepted treatment schemes in the literature. In fibromyalgia syndrome, there is no study in the literature. It was planned to include at least 30 patients aged 18-65 years who were admitted to İzmir Katip Çelebi University Atatürk Training and Research Hospital Physical Medicine and Rehabilitation Outpatient Clinic or hospitalized in the ward and diagnosed with fibromyalgia syndrome according to the 2016 criteria. This study has a prospective, parallel group, randomized, sham-controlled study design. A total of 30 fibromyalgia patients will be randomized into 2 groups and will receive a total of 10 sessions of transcranial magnetic stimulation to the primary motor cortex with intermittent theta bust stimulation technique or sham application. Patients will continue their current fibromyalgia treatment.Numeric Rating Scale-pain intensity (NRS-pain), revised Fibromyalgia Impact Questionnaire (FIQR), Pain Catastrophizing Scale (PCS), Hospital Depression Anxiety Scale (HADS) will be used in the evaluation of the patients.",[129,31,130],"Fibromyalgia","Pain",[129,132,133,134,135,136],"intermittent theta burst stimulation","pain","Pain Catastrophizing","Revised Fibromyalgia Impact Questionnaire","Hospital Anxiety and Depression Scale","2025-03-13",{"date":139,"type":51},"2025-03-18",{"date":137,"type":51},{"date":142,"type":21},"2027-04-01",{"name":144,"class":58},"Izmir Katip Celebi University",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":162,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":59},"100518180","randomized-controlled-study-of-optical-3d-navigated-repetitive-transcranial-magnetic-stimulation-for-achalasia-100518180","NCT06027190","Randomized Controlled Study of Optical 3D Navigated Repetitive Transcranial Magnetic Stimulation for Achalasia.","To Investigate the Clinical Efficacy of Optical 3D Navigation Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Achalasia, Optimize the Treatment Parameters, and Provide a Noninvasive Treatment Strategy for Achalasia","Inclusion Criteria:\n\n* Aged more than 18 years old, less than 75 years old;\n* Clinical symptoms evaluation, HREM, esophageal barium meal examination confirmed the diagnosis of achalasia;\n* Willing to sign informed consent.\n\nExclusion Criteria:\n\n* Presence of metal hardware in close contact with the discharge coil (e.g., cochlear implant, internal pulse generator, or drug pump). Note: Cochlear implants include electrodes, magnets, loop antennas, and electronic chips under the scalp implanted in the cochlea;\n* Intracranial metal implants;\n* Patients with cardiac pacemakers, vagal nerve stimulation (VNS) systems, spinal cord stimulators, and deep brain stimulation implanted with pulse generators should be used with caution;\n* People at higher risk of noisy hearing loss and patients with hypoacusis symptoms should be used with caution;\n* Pregnancy;\n* Severe or recent heart disease;\n* Personal history of epilepsy, use of known drugs that lower the seizure threshold, and other factors that may lower the seizure threshold (e.g., lack of sleep, infection, and alcohol abuse);\n* Increased intracranial pressure;\n* Acute phase of intracranial infection and hemorrhagic disease;\n* Contraindications to MRI examination or claustrophobia;\n* Refusal to sign informed consent.","75 Years",{"count":154,"type":21},112,[24],"The goal of this clinical trial is to investigate the clinical efficacy of repetitive transcranial magnetic stimulation in the treatment of achalasia in patients diagnosed with achalasia by comprehensive evaluation of clinical symptoms, HREM, and barium meal examination, optimize rTMS treatment parameters, and provide an effective and noninvasive new treatment strategy for achalasia. The main questions it aims to answer are:\n\n1. To investigate the clinical efficacy of individualized treatment of achalasia with optical 3D navigation repetitive transcranial magnetic stimulation.\n2. Optimize rTMS parameters to achieve the best clinical treatment.\n\nParticipants will need to fill out the Eckardt score scale and SF-36 quality of life scale, undergo cranial T1 structural magnetic resonance for functional connectivity analysis, and select the brain region with the strongest positive functional connectivity to the DMV as the rTMS target. All patients were randomly divided into four groups: sham-rTMS group, 5Hz-rTMS group, 10Hz-rTMS group, and 30Hz-rTMS group, and each group received acute and chronic stimulation, respectively. In the acute stimulation stage, patients only need to do rTMS once, and HREM and HRV detection are given before and after rTMS (stimulation for 1s, interval for 4s, 10 pulses per second, receiving a total of 3000 pulses); in the chronic stimulation stage, patients receive 25 minutes of rTMS actual stimulation or sham stimulation each time, lasting for 20 times, which is completed within 30 days, and the actual stimulation parameters are the same as those of acute stimulation, and the sham stimulation coil is consistent with the appearance and sound of proper stimulation, but there is no substantial stimulation. High-definition esophageal manometry, timed barium meal, heart rate coefficient of variation, and serum neurotransmitters were performed before and after chronic stimulation. Finally, a weekly telephone follow-up was performed for 12 weeks, including Eckardt score and SF-36 quality of life scale.",[158,159,160,161],"Esophageal Achalasia","Transcranial Magnetic Stimulation, Repetitive","Vagus Nerve Motor Disorder","Functional Magnetic Resonance Imaging",[163,164,165,166],"Achalasia","rTMS","fMRI","Non-invasive","2023-09-15",{"date":169,"type":51},"2023-09-21",{"date":171,"type":21},"2024-01-01",{"date":173,"type":21},"2026-12-31",{"name":175,"class":58},"Zhang Nina"]